Collectively, these data demonstrate a strong synergy of AZD1775 and SRA737 combination in 2D CRPC and NEPC cell cultures and 3D tumor spheroids, suggesting that the combined inhibition of WEE1 and CHK1 may be an effective treatment for advanced prostate cancer. The gene discussed is WEE1; the disease is prostate carcinoma.